Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVE4P3)

• Drug Name: AZD1704 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Pain	MG30-MG3Z	Discontinued in Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMVE4P3

Molecule-Related Drug Atlas

Drug(s) Targeting Cannabinoid receptor 1 (CB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[3]
NABILONE	DMVRYT2	Insomnia	7A00-7A0Z	Approved	[4]
Orlistat	DMRJSP8	Obesity	5B81	Approved	[5]
SR141716A	DMCO5JZ	Obesity	5B81	Approved	[6]
Tebipenem	DMVSX6O	Urinary tract infection	GC08	Phase 3	[7]
Conatumumab	DM2UOSN	Colorectal cancer	2B91.Z	Phase 2	[2]
GW-42004	DMY3KSU	Lipid metabolism disorder	5C52.Z	Phase 2	[8]
SR-147778	DMNAECP	Obesity	5B81	Phase 2	[9]
Nimacimab	DM21Z68	Diabetic nephropathy	GB61.Z	Phase 2	[10]
AEF0117	DMQ1GH4	Marijuana use disorder	6C41	Phase 2	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cannabinoid receptor 1 (CB1)	TT6OEDT	CNR1_HUMAN	Antagonist	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028889)
• [2] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [3] Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol. 2009 Feb;156(3):397-411.
• [4] Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010.
• [5] Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J Med Chem. 2008 Nov 13;51(21):6970-9.
• [6] Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
• [7] Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
• [8] Company report (Gwpharm)
• [9] Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits 9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.Br J Clin Pharmacol.2013 Jul;76(1):65-77.
• [10] Clinical pipeline report, company report or official report of Bird Rock Bio.
• [11] Clinical pipeline report, company report or official report of Affimed Therapeutics.